Neogen outlines $880M-$885M FY 2027 revenue and $180M-$182M adjusted EBITDA amid 50% R&D increase

Neogen announced its revenue and EBITDA guidance for the fiscal year 2027, which includes a 50% increase in R&D expenses.

AI CATALYST SCORE65 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

NEOG Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-08-26 08:30:32	NEOG	85	S-Class	View Report →
2026-07-30 16:58:51	NEOG	65	Mid	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-08-26 11:33:57	LLY	85	Mid	View Report →
2026-08-26 08:30:23	TRUP	45	Row	View Report →
2026-08-25 14:26:29	MRNA	90	S-Class	View Report →
2026-08-25 14:21:10	LLY	40	Row	View Report →
2026-08-25 13:22:05	LLY	75	Mid	View Report →
2026-08-25 12:57:21	MCK	85	S-Class	View Report →
2026-08-25 10:34:43	MRK	85	S-Class	View Report →
2026-08-25 10:05:37	MRNA	75	Mid	View Report →
2026-08-25 07:13:30	AVAH	40	Row	View Report →
2026-08-25 07:13:28	AVAH	40	Row	View Report →
2026-08-25 00:02:12	AVAH	40	Row	View Report →
2026-08-24 17:17:01	MRNA	85	S-Class	View Report →
2026-08-24 16:11:14	LLY	75	Mid	View Report →
2026-08-23 11:45:23	CSTL	85	S-Class	View Report →
2026-08-22 22:04:03	MRNA	85	S-Class	View Report →
2026-08-22 03:43:04	MRNA	85	S-Class	View Report →
2026-08-21 03:19:03	CBLL	40	Row	View Report →
2026-08-20 19:04:01	MRNA	50	Row	View Report →
2026-08-20 15:17:17	RVTY	75	Mid	View Report →
2026-08-20 14:27:55	MRK	50	Row	View Report →
2026-08-20 11:22:35	HUM	50	Row	View Report →
2026-08-20 09:04:00	MRNA	95	S-Class	View Report →
2026-08-20 09:03:55	MRNA	75	Mid	View Report →
2026-08-20 08:35:32	MRNA	95	S-Class	View Report →
2026-08-19 20:59:49	LLY	75	Mid	View Report →
2026-08-19 19:50:04	MRNA	85	S-Class	View Report →
2026-08-19 18:42:43	MRNA	90	S-Class	View Report →
2026-08-19 17:59:36	REGN	85	S-Class	View Report →
2026-08-19 17:24:58	MRNA	85	S-Class	View Report →
2026-08-19 14:21:07	MRNA	90	S-Class	View Report →